"Japan Pharmaceuticals & Healthcare Report Q4 2012" Now Available at Fast Market Research
BMI View: The prospects for Japan's pharmaceutical market over the medium term are very positive. The country has one of the largest pensionable populations, healthcare is readily accessible, the government appreciates investment in biomedical research and the regulatory regime balances the requirements of the major stakeholders. The key downside risk in the world's second-largest pharmaceutical market is a negative macroeconomic adjustment, such as a domestic debt crisis, which would affect public and private spending on medical services. Headline Expenditure Projections...
View full press release